MedTrace Logo

Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

NCT00735709 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 560

Last updated 2013-12-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effectiveness and safety of vortioxetine, once daily (QD), in patients with Major Depressive Disorder.

Conditions

Interventions

DRUG

Vortioxetine

Encapsulated immediate-release vortioxetine tablets

DRUG

Placebo

Vortioxetine placebo-matching capsules

Sponsors & Collaborators

  • H. Lundbeck A/S

    collaborator INDUSTRY

  • Takeda

    lead INDUSTRY

Principal Investigators

  • Medical Director Clinical Science · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2009-07-31
Completion
2009-08-31

Countries

  • Australia
  • Czechia
  • France
  • Germany
  • Latvia
  • Lithuania
  • Malaysia
  • Netherlands
  • Poland
  • Russia
  • South Africa
  • South Korea
  • Taiwan
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00735709 on ClinicalTrials.gov